|
|
|
| Analysis of the Efficacy and Mechanism of Acetylglutamine Combined with Edaravone in the treatment of Cerebral Infarction |
| LIU Yuan, DAI Taicheng, SHI Peng |
| Xianyang Hospital of Yan'an University, Shaanxi Xianyang 712000, China |
|
|
|
|
Abstract Objective: To analyze the efficacy and mechanism of acetylglutamine combined with edaravone in treatment of cerebral infarction. Methods: 400 patients of cerebral infarction who received therapy from February 2017 to February 2018 in our hospital were selected as research objects, according to the simple random number table, those patients were divided into the 210 cases of the observation group and the 190 cases of the control group, on the basis of routine treatment, the control group was treated with edaravone, and the observation group was treated with acetylglutamine on the basis of the control group, continuous treatment of 14d. The clinical efficacy, the changes of serum Galectin-3, NPY, GM-CSF, neurological function (NIHSS score), activity of daily living (Barthel index) and adverse reactions were compared between the two groups. Results: After treatment, the total effective rate of the observation group was 91.43% (192/210), which was significantly higher than that of the control group 84.21% (160/190) (P<0.05). There were significant differences in serum Galectin-3, NPY, GM-CSF, NIHSS score and Barthel index between the observation group and the control group after treatment [(7.89±1.15)μg/L vs(9.65±1.70)μg/L, (51.82±4.57)ng/Lvs(70.51±6.82)ng/L,(0.42±0.05)μg/L vs(0.67±0.09)μg/L,7.08±1.17)scores vs(8.29±1.64)scores,(64.02±8.41)scores vs(57.39±7.23)scores](P<0.05). During treatment, the total incidence of adverse reactions was 6.67% (14/210) and 5.79%(11/190) respectively, there was no significant difference between the two groups(P＞0.05). Conclusion: The use of Acetylglutamide combined with edaravone in patients with cerebral infarction has a significant effect and can promote the recovery of nervous function. Its internal mechanism may be related to the reduction of the expression of serum Galectin-3, NPY and GM-CSF. It has high clinical value.
|
|
|
|
|
|
[1] 兰天,呼日勒特木尔.脑卒中流行病学现状及遗传学研究进展[J].疑难病杂志,2015,14(9):986~989.
[2] 王班,关天嘉,尤莉莉,等.我国缺血性脑卒中残疾情况及其影响因素分析[J].中国全科医学,2016,19(2):216~219.
[3] Dong H, Wang ZH, Zhang N, et al. Serum galectin-3 level, not galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke[J]. Oncotarget, 2017, 8(65): 109752~109761.
[4] 陈赛,张丙宏.神经肽Y在脑损伤性疾病中的研究进展[J].医学综述,2016,22(14):2737~2740.
[5] Watanabe K, Tanaka M, Yuki S, et al. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?[J].Clin Biochem Nutr, 2018, 62(1): 20~38.
[6] Yang X. Conformational dynamics play important roles upon the function of N-acetylglutamate kinase[J]. Appl Microbiol Biotechnol, 2017, 101(9): 3485~3492.
[7] 中华医学会神经病学分会中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246~257.
[8] 涂雪松.缺血性脑卒中的流行病学研究[J].中国临床神经科学,2016,24(5):594~599.
[9] Ke J, Jing M. Analysis of treatment effect of urinary kallidinogenase combined with edaravone on massive cerebral infarction[J]. Biomed Rep, 2016, 5(2): 155~158.
[10] 陈耀武,陈一峰,毛和明,等.乙酰谷胺酰联合依达拉奉治疗老年重度颅脑损伤的疗效观察[J].中国实用神经疾病杂志,2014,17(18):106~107.
[11] Rahimian R, Beland LC, Kriz J. Galectin-3: mediator of microglia responses in injured brain[J]. Drug Discov Today, 2018, 23(2): 375~381.
[12] Chen S, Bennet L, McGregor AL. Delayed varenicline administration reduces inflammation and improves forelimb use following experimental stroke[J].Stroke Cerebrovasc Dis, 2017, 26(12): 2778~2787 |
|
|
|
2019, Vol. 25 
